Northwest & Ethical Investments L.P. Purchases 38,755 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Northwest & Ethical Investments L.P. raised its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 119.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 71,139 shares of the company's stock after purchasing an additional 38,755 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Bausch Health Companies were worth $574,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Bausch Health Companies in the third quarter valued at approximately $938,000. SG Americas Securities LLC boosted its holdings in Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after acquiring an additional 1,263,706 shares during the last quarter. Range Financial Group LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter worth $1,004,000. Geode Capital Management LLC grew its stake in shares of Bausch Health Companies by 20.5% in the 3rd quarter. Geode Capital Management LLC now owns 636,082 shares of the company's stock worth $6,448,000 after acquiring an additional 108,269 shares in the last quarter. Finally, Goldentree Asset Management LP raised its holdings in shares of Bausch Health Companies by 31.0% in the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company's stock valued at $239,552,000 after purchasing an additional 6,958,717 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BHC. Royal Bank of Canada cut their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating on the stock in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $7.42.

Remove Ads

Bausch Health Companies Trading Down 2.8 %

Shares of NYSE BHC traded down $0.20 during midday trading on Wednesday, hitting $6.81. The company's stock had a trading volume of 2,569,351 shares, compared to its average volume of 2,710,015. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -56.70, a P/E/G ratio of 0.37 and a beta of 0.59. The stock has a fifty day moving average price of $7.12 and a 200 day moving average price of $7.72. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, equities research analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.